Autoantibodies to Abl and Bcr proteins

Leukemia

Volumn 14, Issue 9, 2000, Pages 1661-1666

  Talpaz, M ^a   Qiu, X ^a,b   Cheng, K ^a,b   Cortes, J E ^a   Kantarjian, H ^a   Kurzrock, R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Abl; Antibody; Bcr; Chronic myelogenous leukemia

Indexed keywords

AUTOANTIBODY; BCR ABL PROTEIN; CHIMERIC PROTEIN; PROTEIN ANTIBODY;

ANTIGEN RECOGNITION; ARTICLE; BACULOVIRUS; BLAST CELL CRISIS; CANCER IMMUNOLOGY; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOPRECIPITATION; LEPIDOPTERA; LEUKEMIA CELL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 0033835428     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401870     Document Type: Article

References (43)

1. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity
2. The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine kinase activity
3. Fused transcript of ABL and BCR genes in chronic myelogenous leukaemia
4. The molecular genetics of Philadelphia chromosome positive leukemias
5. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leuaemia
6. Immune responses to chronic myeloid leukaemia
7. Graft-versus-leukemia following allogeneic bone marrow transplantation: Emergence of cytotoxic T lymphocytes reacting to host leukaemia cells
8. Recognition of peptides corresponding to the joining region of p210(BCR-ABL) protein by human T cells
9. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors
10. Specific human cellular immunity to bcr-abl oncogene-derived peptides
11. Cellular immune responses to autologous chronic myelogenous leukemia cells in vitro
12. Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-α
13. Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukemia after in vitro treatment with interferon-α (Wellferon)
14. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome
15. KBM-7, a human myeloid leukemia cell line with double Philadelphia chronosomes lacking normal c-ABL and BCR transcripts
16. Establishment of a Ph1-positive human cell line (BV173)
17. Natural antibodies against tubulin, actin, myoglobin, thyroglobulin, fetuin, albumin, and transferrin are present in normal human sera and monoclonal immunoglobuins from multiple myeloma and Waldenstrom's express similar antibody specificities
18. Polyreactive IgM antibodies in the circulation are masked by anitgen binding
19. Naturally occurring autoantibodies against nine common antigens in human sera. Detection, isolation and characterization
20. The emerging concept of pathogenic natural autoantibodies
21. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer
22. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer
23. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers
24. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot
25. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer
26. Detection of circulating antibodies against c-myc protein in cancer patient sera
27. Presence of circulating anti-c-myb oncogene produce antibodies in human sera
28. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lylmphoma
29. Towards understanding the pathogenesis of rheumatic fever
30. Molecular mimicry: Can epitope mimicry induce auto-immune disease?
31. Autoantibody-defined epitopes on nuclear antigens are conserved, conformation-dependent and active site regions
32. Recent developments in the understanding of antinuclear autoantibodies
33. Cell cycle-associated autoantibodies: Markers for autoimmunity and probes for molecular cell biology
34. The nuclear compartment of living cells is not an absolute immunologically sequestered site: Evidence for spontaneous intranuclear entry of lupus autoantibodies to living cells
35. Antibody to nuclear ribonucleoprotein penetrates live human mononuclear cells through Fc receptors
36. Autoantibodies in systemic lupus erythematosus
37. The penetration of autoantibodies into cells may induce tolerance to self by apoptosis of autoreactive lymphocytes and cause autoimune disease by dysregulation and/or cell damage
38. Donor leukocyute transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
39. Induction of graft versus host disease as immunotherapy for relapsed chronic myeloid leukemia
40. Donor lymphocyte infusions
41. T cell immunity to the joining region of p210 BCR-ABL protein
42. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia: Analysis by polymerase chain reaction of individual colonies
43. Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients: Identity of key contact residues in the B-cell and T-cell epitopes